$2.5M/4-Year DoD CDMPR Contract to BioSensics

I am excited to share that BioSensics has been awarded a ~$2.5M/4-year contract through the DoD Congressionally Directed Medical Research Programs (CDMRP). This contract will facilitate the advancement of our efforts to develop and validate remote measurement technologies and digital biomarkers for frontotemporal lobar degeneration (FTLD) syndromes. These syndromes encompass a range of neurodegenerative disorders impacting both movement and cognitive function, and they are closely associated with Alzheimer’s disease.

In 2022, BioSensics was awarded a $2.5M/3-year SBIR grant by the National Institute on Aging to develop a multi-modal remote monitoring solution for FTLD syndromes and validate it in progressive supranuclear palsy. Subsequently, in January 2024, BioSensics received the AFTD-ALS Association Digital Assessment Tools for FTD and ALS Award. This award aims to support a pilot study using the developed solution in frontotemporal dementia (FTD) and corticobasal syndrome (CBS).

The DoD CDMRP award will expand our efforts in FTD and CBS by recruiting a diverse patient cohort at Massachusetts General Hospital (led by Anne-Marie Wills, M.D., and Brad Dickerson, M.D.), and Johns Hopkins University (led by Alex Pantelyat, M.D., and Chiadi Onyike, M.D.).